Cellectis Reports Financial Results for First Quarter 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca
Stay updated with breaking news from Bing Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca
A report from CB Insights' State of Venture for the first quarter of 2024 showed that deal-making dropped to a 7-year low in Q1, and was the eighth straight quarter of a drop in equity deal volume.
. Cellectis announced completion of the additional equity investment of $140M by AstraZeneca . Cash position of $143 million as of March 31
NEW YORK, May 02, 2024 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the...
Bringing Taiwan to the World and the World to Taiwan